

ASSESSMENT OF THE WIDE-RESISTANT *PSEUDOMONAS AERUGINOSA* OUTBREAK AT A UNIVERSITY HOSPITAL IN BRAZIL: HAVE WE LOST THIS WAR?!

Henry Pablo Lopes Campos e Reis¹, Ana Beatriz Ferreira Rodrigues², Júlio Cesar Castro Silva², Lia Pinheiro de Lima², Talita Lima Quinaher², Thaynara Carvalho de Freitas², Cala Mônica Porto Pereira², Breno Queiroz de Araujo¹, Paulo Cesar Pereira de Sousa¹, Lícia Borges Pontes¹, Jorge Luiz Nobre Rodrigues¹

BACKGROUND

Resistance profile analysis in *Pseudomonas aeruginosa* isolates is extremely important to prevent its transmission and to detect outbreaks. Broadly resistant strains (BR) have a high mortality rate in invasive infections. By analyzing the clinical and microbiological characteristics of these infections, one can define more effective actions in a nosocomial outbreak setting in a university hospital in Brazil.

METHODS

From January to September 2019, 13 patients from the oncohematology services and intensive care unit (ICU) followed by the stewardship program of a public university hospital in Brazil had Pseudomonas aeruginosa (PsA) BR infection.

- Multidrug-resistant (MDR): resistant to three or more antimicrobial classes;
- Extensively-resistant (XDR): sensitive to a maximum of two antimicrobial classes;
- Pandrug-resistant (PDR) has been defined as resistant to all antimicrobial classes.¹

Bacterial samples were identified by the automated VITEK[®]2 system (BioMérieux). The resistance pattern was defined based on the CLSI-M100 2019 criteria. Colistin sensitivity was assessed by the colistin drop test.² The modified carbapenemic inactivation method (mCIM) was performed by disk diffusion.

• This study was approved by the hospital's research ethics committee (Nº 2.945868)

RESULTS

The 13 strains of PsA were isolated from 84.6% (11/13) blood cultures and 15.4% (2/13) tracheal aspirates, being 76.9% (10/13) from the oncohematology unit and 23.1% (3/13) of the ICU. The resistance profile was 23.1% (3/13) strains sensitive to amikacin, gentamicin, ciprofloxacin and colistin (PsA MDR); 61.5% (8/13) colistin-only (PsA XDR) sensitive strains; 15.4% (2/13) strains resistant to all classes (PsA PDR). 69.2% (9/13) of the strains were mCIM positive, in which the therapeutic option was ceftazidime/avibactam in combination with polymyxin. Regarding the sites of infection and use of devices, 53.8% (7/13) of the patients developed the infection after the use of central venous catheter and/or mechanical ventilation. The mortality rate was 76.9% (10/13).



¹HOSPITAL UNIVERSITÁRIO WALTER CANTÍDIO, FORTALEZA, BRAZIL, ²UNIVERSIDADE FEDERAL DO CEARÁ, FORTALEZA, BRAZIL





The investigation of the outbreak of *Pseudomonas aeruginosa* highlights the importance of infectious surveillance of this pathogen with this resistance profile, to better understand the causalities, minimize its damage and reduce potential recurrence of new outbreaks.

REFERENCES

- 1. Pearson et al. Consenso latinoamericano para definir, categorizar y notificar patógenos multirresistentes, con resistencia extendida o panresistentes. Rev Panam Salud Publica [Internet]. 2019.
- 2. Pasteran et al., Development and validation of simple tests (agar spot, colistin drop, 1ml-broth disk elution MIC and tablet pre-diffusion) as an alternative to improve accuracy in screening chromosomal and plasmid-mediated colistin resistance in Gram-negative bacilli. 2018. 28th ECCMID.

Contact: henrypabloreis@yahoo.com.br +55 85 999851742